Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Sana Biotechnology Inc

SANA ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$3.85

▼ -1.79%

Market Cap $1.15B · Vol 451.39K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.15B

Small Cap

Div Yield

N/A

EPS Growth

+27.04%

YoY

RSI (14)

54.15

Momentum

Beta

2.16

vs Market

52W High

$6.55

41.22% below

52W Low

$2.62

47.23% above

Volume

451.39K

Avg 827.91K

P/B

6.75

Price-to-book

ROE

-118.70%

Return on equity

Free Float

93.92%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Sana Biotechnology Inc (SANA) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SANA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.04%

+13.24%

+30.07%

+0.79%

YTD

-5.41%

+29.19%

-33.62%

-84.44%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-244,166,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-118.70%
ROA · ROIC	-53.20% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	6.75
P/FCF	N/A
EPS Growth	+27.04%
Outstanding Shares	299.36M

Technical Indicators

50-Day SMA	$3.61
200-Day SMA	$3.70
RSI (14)	54.15
Beta	2.16
52-Week High	$6.55
52-Week Low	$2.62

Volume Today	451.39K
Avg Daily Volume (30D)	827.91K
Relative Volume	0.55x
Volatility (10D)	51.92
Volatility (30D)	66.55
Free Float	93.92%

Analyst Consensus

BUY

Current Price $3.85

Mean Target $8.43

52W Low$2.62 52W High$6.55

Current

Target

$2.62 $6.55

Current Analyst target

+118.92% upside potential · 10 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00N5BMH70

ISINUS7995661045

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.57% ARGX.BR argenx SE -2.06% ARGX argenx SE -1.93% INSM Insmed Inc -0.31% 2269.HK WuXi Biologics (Cayman) Inc -3.00%

Company Profile

Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), oncology, and B cell mediated autoimmune diseases. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline products include SC451 and UP421. SC451 is its HIP-edited product candidate for the treatment of type 1 diabetes. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. Its ex vivo cell engineering platform is focused on engineering hypoimmune cells that engraft, function, and persist in patients by evading immune rejection.